Brave Asset Management Has Cut Its Position in Gilead Sciences (GILD) by $545,422 as Shares Rose; Comcast Cl A (CMCSA) Shareholder Catawba Capital Management Cut Position by $665,600

April 17, 2018 - By Dolores Ford

Comcast Corporation (NASDAQ:CMCSA) Logo

Brave Asset Management Inc decreased its stake in Gilead Sciences Inc (GILD) by 30.39% based on its latest 2017Q4 regulatory filing with the SEC. Brave Asset Management Inc sold 7,682 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 17,594 shares of the health care company at the end of 2017Q4, valued at $1.26 million, down from 25,276 at the end of the previous reported quarter. Brave Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $98.71B market cap company. The stock increased 1.37% or $1.02 during the last trading session, reaching $75.71. About 2.15 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Catawba Capital Management decreased its stake in Comcast Corp Cl A (CMCSA) by 47.49% based on its latest 2017Q4 regulatory filing with the SEC. Catawba Capital Management sold 16,640 shares as the company’s stock declined 19.10% with the market. The institutional investor held 18,402 shares of the television services company at the end of 2017Q4, valued at $737,000, down from 35,042 at the end of the previous reported quarter. Catawba Capital Management who had been investing in Comcast Corp Cl A for a number of months, seems to be less bullish one the $153.97B market cap company. The stock decreased 1.13% or $0.38 during the last trading session, reaching $33.15. About 12.89M shares traded. Comcast Corporation (NASDAQ:CMCSA) has declined 11.10% since April 17, 2017 and is downtrending. It has underperformed by 22.65% the S&P500.

Brave Asset Management Inc, which manages about $193.32M and $192.00M US Long portfolio, upped its stake in Royal Dutch Shell Plc by 4,613 shares to 33,505 shares, valued at $2.29 million in 2017Q4, according to the filing. It also increased its holding in Jpmorgan Chase & Co (NYSE:JPM) by 15,406 shares in the quarter, for a total of 17,906 shares, and has risen its stake in J2 Global Inc (NASDAQ:JCOM).

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It is negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. The Minnesota-based Leuthold Group Limited Company has invested 0.68% in Gilead Sciences, Inc. (NASDAQ:GILD). Cohen Klingenstein Ltd Liability Corp stated it has 0.13% in Gilead Sciences, Inc. (NASDAQ:GILD). Plante Moran Advsr Limited Company accumulated 2,843 shares. 28,659 were accumulated by Hemenway Trust Ltd Liability. Cohen Lawrence B owns 23,050 shares or 1.05% of their US portfolio. Westport Asset Management has invested 0.86% in Gilead Sciences, Inc. (NASDAQ:GILD). Nichols Pratt Advisers Llp Ma holds 0.97% or 155,005 shares in its portfolio. Integral Derivatives Limited Liability reported 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Canada Pension Plan Board holds 0.47% or 3.48 million shares. Gw Henssler holds 1.14% in Gilead Sciences, Inc. (NASDAQ:GILD) or 170,470 shares. Point72 Asset LP holds 0.07% or 241,904 shares in its portfolio. Dekabank Deutsche Girozentrale invested 0.62% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Da Davidson &, Montana-based fund reported 76,849 shares. Fort LP invested in 278,035 shares. Fil Ltd has invested 0.42% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD).

Since January 2, 2018, it had 0 insider purchases, and 17 insider sales for $39.51 million activity. 5,833 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $437,588 were sold by Cogan John Francis. $4.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by WILSON GAYLE E. Another trade for 15,000 shares valued at $1.11 million was made by Alton Gregg H on Tuesday, January 2. Another trade for 5,000 shares valued at $401,566 was made by Washington Robin L on Wednesday, February 21. Meyers James R also sold $8.02 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 16.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 EPS, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07 billion for 11.90 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, November 8, the company rating was maintained by Mizuho. The firm has “Buy” rating by William Blair given on Thursday, August 31. The firm has “Outperform” rating given on Wednesday, September 14 by Credit Suisse. William Blair maintained the shares of GILD in report on Wednesday, June 14 with “Buy” rating. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, February 7. The firm has “Overweight” rating by Piper Jaffray given on Wednesday, February 3. The company was maintained on Wednesday, February 3 by Credit Suisse. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, March 23 with “Outperform” rating. As per Tuesday, May 30, the company rating was maintained by Cowen & Co. The rating was upgraded by Citigroup to “Buy” on Tuesday, January 30.

Among 32 analysts covering Comcast Corporation (NASDAQ:CMCSA), 23 have Buy rating, 1 Sell and 8 Hold. Therefore 72% are positive. Comcast Corporation had 82 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Monday, August 14. The firm earned “Buy” rating on Tuesday, December 8 by Nomura. The firm has “Neutral” rating given on Tuesday, June 20 by Moffett Nathanson. The stock has “Neutral” rating by Macquarie Research on Monday, January 4. Pivotal Research maintained it with “Buy” rating and $95 target in Thursday, January 26 report. The stock of Comcast Corporation (NASDAQ:CMCSA) earned “Buy” rating by Goldman Sachs on Wednesday, May 4. The firm has “Buy” rating by Moffett Nathanson given on Wednesday, August 19. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, April 28 report. The company was maintained on Thursday, July 6 by Jefferies. The firm has “Sector Weight” rating by Pacific Crest given on Friday, January 27.

Analysts await Comcast Corporation (NASDAQ:CMCSA) to report earnings on April, 25 before the open. They expect $0.59 EPS, up 11.32% or $0.06 from last year’s $0.53 per share. CMCSA’s profit will be $2.74 billion for 14.05 P/E if the $0.59 EPS becomes a reality. After $0.49 actual EPS reported by Comcast Corporation for the previous quarter, Wall Street now forecasts 20.41% EPS growth.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>